Compare DexCom, Inc. (DXCM) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kimberly Clark Corp — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while Kimberly Clark Corp trades at $98.11 (market cap $32.51B). The key difference: DexCom, Inc. and Kimberly Clark Corp are close in size by market cap, and Kimberly Clark Corp pays a 5.24% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Kimberly Clark Corp for 93 Days on average.
| DXCM | KMB | |
|---|---|---|
Market Cap | $31.86B | $32.51B |
Volume | 3,607,070 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $121.44 |
52-Week Low | $54.84 | $93.05 |
Typical Hold Time | 62 Days | 93 Days |
Enterprise Value | $31.32B | $38.07B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Kimberly-Clark (KMB) trades at $98.02, up 1.6% on the day, showing modest recovery from recent weakness. The stock faces bearish technical signals with support at $96 and resistance at $98. Fundamentally, the company maintains strong profitability with 11.79% net margins and consistent dividend payments, though revenue declined to $16.45B in 2025. Recent executive transitions and the pending Kenvue acquisition create both uncertainty and strategic opportunity.
KMB offers a compelling dividend yield above 5% with 54 consecutive years of increases, but faces execution risks from the Kenvue integration. Analyst consensus targets $117.25 (19% upside) with mixed sentiment (32% buy, 58% hold). The stock presents value for income investors but requires careful monitoring of acquisition progress and cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
